TRCT
ADAG

Tower Research Capital (TRC)’s Adagene ADAG Stock Holding History

Tower Research Capital (TRC)’s Portfolio ADAG Stock Details ADAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,627
Closed -$7K – 6014
2022
Q2 		$7K Sell
3,627
-1,365
-27% -$4.13K ﹤0.01% 4755
2022
Q1 		$17K Buy
4,992
+3,714
+291% +$23.4K ﹤0.01% 3670
2021
Q4 		$10K Buy
+1,278
New +$13.1K ﹤0.01% 4528

Other funds holding ADAG

HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SVI
Strategic Vision Investment Hong Kong $157M AUM 125.87% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
EFM
E Fund Management Guangzhou, China $3.37B AUM

Tower Research Capital (TRC)'s ADAG Position: Q3 2022 in Review

Tower Research Capital (TRC) sold out of Adagene (ADAG) in Q3 2022, closing a stake of 3,627 shares — an estimated $7K sold.

Tower Research Capital (TRC) first reported a position in ADAG in Q4 2021 and held it in 3 quarters. The position peaked at $17K in Q1 2022. 11 funds tracked by Wall St. Rank hold ADAG as of Q3 2022.

  • Tower Research Capital (TRC) reported no remaining Adagene position as of Q3 2022 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 3,627 Adagene shares in Q3 2022, an estimated $7K.
  • Tower Research Capital (TRC) first reported a position in Adagene in Q4 2021 and held it in 3 quarters.
  • Tower Research Capital (TRC)'s Adagene position peaked at $17K in Q1 2022.
  • 11 funds tracked by Wall St. Rank held Adagene as of Q3 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2022, filed 10 Nov 2022.